1Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T (H)17 eytokine, mediates IL-23-indueed dermal inflammation and acanthosis[J]. Nature,2007,445(7128) :648-651.
2Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27:related but functionally distinct regulators of inflammation[J]. Annu Rev Immunol, 2007,25 : 221-242.
3Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells[J]. Nat Immunol,2007,8(9) :950-957.
4Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid[J]. Science, 2007,317(5835):256-260.
5Elias KM, Laurence A, Davidson TS, et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway[J]. Blood, 2008,111(3): 1013-1020.
6Ma HL,Liang S, Li J, et al. IL-22 is required for Thl7 cell- mediated pathology in a mouse model of psoriasis-like skin inflarnmation[J]. J Clin Invest, 2008,118(2) : 597-607.
7Cummings JR,Ahmad T,Geremia A,et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype[J]. Inflamm Bowel Dis, 2007,13 (9) : 1063-1068.
8Helmick CG,Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part Ⅰ[J]. Arthritis Rheum, 2008,58 (1) : 15-25.
9Wendling D, Cedoz JP, Racadot E, et al. Serum IL- 17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis[J]. Joint Bone Spine, 2007,74 (3) : 304-305.
10Singh R,Aggarwal A,Misra R. Thl/Thl7 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy[J]. J Rheumatol, 2007, 34 ( 11 ):2285- 2290.
同被引文献10
1Vanderlinden S J, Valkenburg H A, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A propos- al for modification of the New York criteria [J]. Arthritis Rheum, 1984, 27(4) : 361-368.
2Garrett S, Jenkinson T, Kennedy L G, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index [J]. Rheumatol, 1994, 21(12) : 2286-2291.
3Conde J, Scotece M, Gomez R, et al. At the crossroad between immunity and metabolism: focus on leptin [J]. Expert Rev Clin Immunol, 2010, 6(5) : 801-808.
4Park M C, Chung S J, Park Y B, et al. Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis [J].Joint Bone Spine, 2009, 76(2): 170-175.
5Park M C, Lee S W, Choi S T, et al. Serum leptin levels correlates with IL-6 levels and disease activity in patients withankylosing spondylitis[J]. Scand J Rheumatol, 2007, 36(2): 101-106.
6Derdemezis C S, Filippatos T D, Voulgari P V, et al. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment [J]. Clin Exp Rheumatol, 2010, 24(28): 880-883.
7Toussirot E, Streit G, Nguyen N U, et al. Adipose tissue, serum adipokines, and ghrelin levels in patients with ankylosing spondylitis [J]. Metabolism, 2007, 56(10): 1383-1389.
8Toussirot E, Streit G, Wendling D. The contribution of adipose tissue and adipokines to inflammation in joint disease [J]. Curr Med Chem, 2007, 14(10): 1095-1100.
9Wang X, Lin Z, Wei Q, et al. Expression of IL 23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis [J]. RheumatolInt, 2009, 29(11): 1343-1347.
